Mon. 29 Apr 2024, 8:55am ET
Benzinga
Biotech, News, General
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications –
– IDMC Will Convene Again Ahead of Scheduled IDMC Charter Meeting –
– Next Efficacy and Safety Assessment of All REGAL Patients (n=127) in June 2024 –